CGEN
Compugen Continues to Make Strides in Clinical Advancements and Partnerships
Compugen, a leading biotechnology company, recently reported its second quarter 2026 financial results, highlighting steady advancement across every part of the organization. The company's President and Chief Executive Officer, Dr. Eran Ophir, expressed satisfaction with the progress made during the quarter. The company's clinical pipeline continues